From Seekingalpha · · 40s
Precision BioSciences Shares Phase 1 ELIMINATE-B Data
Precision BioSciences presents Phase 1 ELIMINATE-B results for PBGENE-HBV in chronic hepatitis B.
In brief
Precision BioSciences presents Phase 1 ELIMINATE-B results for PBGENE-HBV in chronic hepatitis B. Precision BioSciences shared Phase 1 ELIMINATE-B data for PBGENE-HBV in chronic hepatitis B at AASLD 2026. Originally reported by Seekingalpha.
Company Shares Phase 1 ELIMINATE-B Data
Precision BioSciences presented Phase 1 ELIMINATE-B data for PBGENE-HBV in chronic hepatitis B at AASLD 2026.
Key Executives Attend Investor Update
Naresh Tanna, CFO; Michael Amoroso, CEO; and Cassie Gorsuch, Chief Scientific Officer joined the call.
Hepatology Experts Join Presentation
Dr. Mark Sulkowski from Johns Hopkins Bayview and Dr. MF Yuen from University of Hong Kong provided expert insights.
The key point
Precision BioSciences shared Phase 1 ELIMINATE-B data for PBGENE-HBV in chronic hepatitis B at AASLD 2026.
